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Abstract 15 
Background 16 
Suboptimal glycaemic control in type 2 diabetes (T2D) is common and associated with 17 
psychological barriers.  18 
Aim 19 
We tested whether it was possible to train practice nurses in six psychological skills 20 
(Diabetes 6 (D6)) based on motivational interviewing (MI) and basic cognitive behaviour 21 
therapy (CBT) and whether integrating these with diabetes care was associated with 22 
improved glycaemic control over 18 months compared to standard care. 23 
Design and Setting 24 
A two-arm, single-blind, parallel cluster randomised controlled trial conducted in primary 25 
care practices (n=24) (ISRCTN trial registration: ISRCTN75776892). 26 
Method 27 
Adult participants (n=334) with T2D and HbA1c ≥69.4 mmol/mol (lowered to ≥64 28 
mmol/mol midstudy to increase recruitment) at least once in previous 18 months and at 29 
recruitment were randomised to receive 12 sessions of either the D6 intervention or standard 30 
care over 12 months. The practices nurses were trained in the six psychological skills and 31 
their competencies were measured by standardised rating scales. All sessions were 32 
audiotaped. The primary outcome was change in HbA1c at 18 months from randomisation; 33 
secondary outcomes were change in systolic and diastolic blood pressure, body mass index, 34 
waist circumference, depressive symptoms, harmful alcohol intake, diabetes-specific distress, 35 
and cost-effectiveness.  36 
 37 
Results 38 
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Using intention-to-treat analysis, there was no significant difference between D6 intervention 39 
and standard care in HbA1c (absolute mean difference -0.79 mmol/mol, 95% CI -5.75–4.18) 40 
or for any of the secondary outcomes. The competency level of D6 nurses was below the 41 
beginner proficiency level and similar to the standard care nurses. 42 
Conclusion 43 
Training nurses in MI and basic CBT to support self-management did not lead to 44 
improvements in glycaemic control or other secondary outcomes in people with T2D at 18 45 
months. It was also unlikely to be cost-effective. Furthermore, the increased contact with 46 
standard care nurses did not improve glycaemic control. 47 
 48 
Keywords: Type 2 diabetes, Self-management, Motivational interviewing, Cognitive 49 
behavioural therapy, Glycaemic control 50 
 51 
How this fits in 52 
The evidence that low intensity psychological interventions to support self-management in 53 
people with poorly controlled type 2 diabetes in primary care setting is limited. 54 
It is not known whether practice nurses can be trained to deliver low intensity psychological 55 
treatments to support self-management in type 2 diabetes. 56 
Training on low intensity psychological interventions based on motivational interviewing and 57 
basic cognitive behaviour therapy led to basic proficiency in these skills but this was not 58 
maintained. 59 
Offering more sessions with practice nurses to support self-management in people with 60 
persistent hyperglycaemia does not lead to improvement in glycaemic control in type 2 61 
diabetes. 62 
63 
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Introduction 64 
Around half of people with type 2 diabetes (T2D) have persistent suboptimal glycaemic 65 
control despite evidence based pathways based on national guidance.1–3 Psychological 66 
factors, such as depressive symptoms and diabetes-specific fears are common in T2D and 67 
associated with reduced self-management.4,5 Addressing these psychological barriers could 68 
lead to improvement in glycaemic control. 69 
Common psychological interventions include motivational interviewing (MI)6 and cognitive 70 
behaviour therapy (CBT).7,8  Recent randomised controlled trials (RCT) suggest that the 71 
effect of low-intensity psychological interventions on glycaemic control is lower than 72 
reported in systematic reviews.9–11  73 
One of the roles of the practice nurse is to support diabetes self-management. Hospital 74 
diabetes specialist nurses can be trained to competently deliver MI and basic CBT skills with 75 
improvement in glycaemic control in type 1 diabetes12 and psychological interventions could 76 
be delivered by nurses in research settings.13 We defined a package of six psychological 77 
skillsets for T2D (Diabetes 6 (D6)) of similar intensity to low-level psychological treatments 78 
for common mental disorders in the NHS.14 We tested in a cluster RCT whether training 79 
practice nurses in D6 skills was associated with increased competency than nurses not receive 80 
the training, and whether the D6 intervention was more effective than standard care in 81 
improving suboptimal glycaemic control in people with T2D over 18 months and in 82 
improving secondary outcomes (such as lipids, depressive symptoms), and if it was cost-83 
effective.  84 
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Method 85 
Trial design 86 
D6 was a pragmatic parallel two-arm cluster RCT design for 18 months. GP practices with 87 
≥6000 patients registered in the Lambeth, Southwark, Lewisham, Wandsworth, and Bexley 88 
Clinical Commissioning Groups (representing a resident population of 1.43 million), were 89 
invited to participate if they had a practice nurse delivering diabetes care. Recruitment of 90 
patients began after each practice consented to randomisation. Randomisation of clusters was 91 
conducted in two phases, as recruitment of practices and patients had slowed down following 92 
the organisational uncertainties preceding the implementation of the Health and Social Care 93 
Act 2012. This Act re-organised the UK’s National Health Service (NHS), dismantling 94 
current organisational structures and creating new ones for funding, management, 95 
accountability and regulation.15  96 
Patients 97 
Inclusion criteria were: adults aged 18–79 years, duration of T2D  for ≥2 years, persistent 98 
suboptimal glycaemic control defined as International Federation of Clinical Chemistry 99 
(IFCC) HbA1c ≥69.4 mmol/mol (National Glycohemoglobin Standardization Program 100 
(NGSP) 8.5%) on two occasions (at least once in the preceding 18 months and the second one 101 
at recruitment) while on at least two oral diabetes medication (metformin and one other), 102 
and/or requiring insulin therapy to ensure that efforts to optimise medical care had been 103 
offered to the patient.15 The IFCC HbA1c was lowered to ≥64 mmol/mol (NGSP 8%) in 104 
Phase 2 to increase recruitment.  105 
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Exclusion criteria were: severe mental disorders; terminal illnesses and end-stage diabetes 106 
complications; morbid obesity (body mass index (BMI) >40 kg/m2 in Phase 1 and >50 kg/m2 107 
in Phase 2); non-ambulatory; no phone/internet access; non-English-speaking; and receiving 108 
psychological treatments elsewhere. Patients who had Patient Health Questionnaire-9 (PHQ-109 
9) depressive scores >20 were excluded if they had psychotic depression or active suicidal 110 
ideation.16  111 
Baseline measures 112 
Baselines measures before randomisation were: age, gender, self-reported ethnicity, 113 
occupation, employment status, and smoking status. Complication status included: 114 
neuropathic ulcer risk by perception of 10g monofilament; retinopathy coding of the most 115 
recent annual standardised digital retinal photography; nephropathy using the urinary 116 
albumin:creatinine ratio (ACR); and history of macrovascular complications.  117 
Randomisation 118 
Randomisation of practices (unit of cluster) was conducted by an independent statistician 119 
using a random number generator to assign equal numbers of practices to each arm at each 120 
phase. For allocation concealment, an independent manager held the randomisation list in 121 
password-locked computer. 122 
Intervention 123 
Group 1: Standard care 124 
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The nurse delivered diabetes care in both groups as recommended by national guidance, 125 
which included diabetes self-management education, monitoring of biomedical status, and 126 
giving clinical information and advice.17 To control for attention, standard care nurses offered 127 
the same number of sessions as D6. This consisted of 12 sessions, each 30 minutes in 128 
duration, over 12 months. The sessions were held in routine primary care clinics and 129 
audiotaped.  130 
 131 
Group 2: Standard care plus Diabetes 6  132 
The theory underlying MI is that the patient’s state of ambivalence (resistance versus 133 
willingness to make lifestyle changes) is the core psychological construct that needs 134 
addressing.6 MI is a directive, counselling style which encourages patients to change 135 
behaviours using collaborative, non-judgmental, and affirming communications. The theory 136 
underlying CBT is that barriers to diabetes self-management are maintained by unhelpful 137 
thoughts (e.g., if I can’t cure diabetes, what’s the point?), unhelpful behaviours (e.g., missing 138 
insulin doses), and distressing emotions (e.g., low mood/anxiety when seeing a high blood 139 
glucose reading).18,19 Identifying and challenging these cognitive barriers are effective in 140 
changing behaviours.20 The D6 nurses were trained to integrate diabetes care with six skills 141 
drawn from MI and CBT, as follows : 1. Active listening; 2. Managing resistance; 3. 142 
Directing change; 4. Supporting self-efficacy; 5. Addressing health beliefs; and 6. Shaping 143 
behaviours. This consisted of 12 sessions, each 30 minutes in duration, over 12 months. The 144 
sessions were held in routine primary care clinics and were audiotaped.  145 
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The Motivational Interviewing Treatment Integrity (MITI) Scale (version 3.1.1)21 and 146 
Behaviour Change Counselling Index (BECCI)22 were used to compare competencies in both 147 
groups. The middle 20 minutes of sessions were rated by two independent psychologists 148 
trained in MITI and the BECCI was rated by a clinical psychologist, blind to treatment 149 
allocation. 150 
Outcomes 151 
The follow-up was reduced from 24 to 18 months secondary to the delays in recruitment. The 152 
primary outcome was change in HbA1c (mmol/mol) from cluster randomisation to 18 months 153 
measured centrally (King’s College Hospital NHS Foundation Trust) by affinity 154 
chromatography (Primus Ultra2, Kansas City, USA). If the study HbA1c were missing at 18-155 
month, we included the 15-month HbA1c as this clinically overlaps with the 3-month 156 
window for 18-month HbA1c. The following secondary outcomes were change in systolic 157 
and diastolic blood pressure using an electronic sphygmomanometer; BMI, and waist 158 
circumference (cm); depressive symptoms using the PHQ-9;16 the Alcohol Use Disorders 159 
Identification Test (AUDIT);23 and the Diabetes Distress Scale, which measures diabetes-160 
specific psychological burden.24 A fasting blood sample was used for HbA1c, total 161 
cholesterol, and triglycerides. 162 
Sample size 163 
An IFCC HbA1c 10.9 mmol/mol (NGSP HbA1c 1%) difference in D6 compared to standard 164 
care was the minimal clinically significant reduction at 18 months, considering that standard 165 
care may produce a 2.2 mmol/mol (NGSP HbA1c 0.2%) reduction in HbA1c (equivalent to a 166 
moderate effect size of d=0.55). Assuming 20% dropout, we needed 360 patients to achieve 167 
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80% power at a two-sided alpha-level of 5%, with 20 practices with 18 patients each per arm. 168 
We assumed two practices per arm would dropout, thus requiring 24 practices with a total 169 
patient sample of 24x18=432 patients. After adjusting for clustering by practice (clustering 170 
intra-correlation coefficient (ICC)=0.05) and an inflation factor of 1.7, the final required 171 
sample size was 81x1.7=138 patients per arm.  172 
We recruited 334 patients of which 231 had at least one follow-up in 24 clusters. The average 173 
cluster size was therefore 10 patients per cluster, smaller than our assumed size of 15 patients 174 
per cluster with a post-hoc power of 77% at two-sided alpha-level of 5%.25 175 
Statistical analysis 176 
Data were analysed using STATA 13. The sample characteristics were described as means 177 
(standard deviation (SD)) or as proportions (percentage). A comparison of patient list size 178 
and Index of Multiple Deprivation (IMD) 2010 rank score by practices that participated 179 
versus those that did not was conducted using Student’s t-test. The IMD 2010 score is a 180 
composite index of relative deprivation at a small area level, based on seven domains of 181 
deprivation: income, employment, health deprivation and disability, education, skills and 182 
training, barriers to housing and services, crime and disorder, and living environment.26 A 183 
linear mixed-effects model estimated group differences in HbA1c levels between D6 and 184 
standard care groups at 18 months. Nurse was included as a random effect as the unit of 185 
randomisation. Secondary outcomes were also analysed using linear mixed models to 186 
estimate group differences at 18 months.  187 
Twenty-nine participants with HbA1c <64 mmol/mol were mistakenly recruited because of 188 
coding errors by the research team during assessment of eligibility and this mistake was only 189 
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discovered after randomisation. Therefore, they were retained for the ITT. We performed a 190 
sensitivity analysis by including a binary covariate of this protocol violation using maximum 191 
likelihood under the missing at random assumption. Sensitivity to missingness in HbA1c was 192 
assessed by investigating and including predictors of missingness in the model and by using 193 
multiple imputation for the missing values of HbA1c. 194 
For further details of the protocol, including the economic evaluation, see Appendix 1. 195 
Results 196 
We invited 116 practices, 26 agreed to participate and two dropped out before randomisation 197 
(Figure 1; Appendix2:Table 1) and 995 potentially eligible participants. Of the 451 who 198 
consented for eligibility, 334 were recruited. Twelve practice clusters were randomly 199 
assigned to standard care (n=164 participants) and 12 to standard care plus D6 (n=170). One 200 
D6 practice dropped out after randomisation, before the nurse received the training, and 201 
before all patients were recruited (those who consented remained in the ITT analysis). Invited 202 
practices that participated (n=24) compared to those that did not (n=89) had higher mean 203 
patient list sizes (12180 (SD=5099) vs. 10091 (SD=3894), p=0.03) but no difference in IMD 204 
score (10049 (SD=6910) versus 12441 (SD=7785), p=0.17). Table 1 presents the baseline 205 
characteristics of the sample.  206 
Figure 1 here; Table 1 here 207 
The mean number of sessions attended was 7.42 (SD=4.4) and 8.20 (SD=4.4) in the D6 and 208 
standard care groups, respectively.  209 
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Primary outcome data at 18-month follow-up were collected for 219 (65.6%) participants and 210 
a further 12 had 15-month HbA1c data, providing 231 participants. There was a non-211 
significant larger proportion with missing HbA1c in the D6 group compared to standard care 212 
(35.9% versus 32.9%, respectively) (Appendix 2:Table 2) and more likely to be 213 
African/Caribbean or Asian/Other ethnicity. In the ITT analysis, there was no significant 214 
difference in mean HbA1c at follow-up in the D6 group compared to the standard care group 215 
(table 2). The ICC for the clustering effect of nurse was 0.02 (95% CI 0.001–0.37). Linear 216 
mixed models showed no significant effects of the intervention on the secondary outcomes 217 
including BMI, blood pressure, fasting triglyceride, or psychological distress (table 2). 218 
Table 2 here 219 
Results were similar for the sensitivity analyses when: using practice as the clustering 220 
variable in place of nurse as cluster; including a binary covariate for the 29 participants with 221 
baseline HbA1c <64 mmol/mol; including ethnicity and history of stroke as predictor of 222 
missingness at follow-up; or using multiple imputation to account for missingness in HbA1c 223 
(Appendix 2:Table 2). There was no evidence of an association between the number of D6 224 
sessions attended and HbA1c at 18 months within the D6 group (-0.44 mmol per additional 225 
session attended, 95% CI -1.28–0.41).  226 
Intervention costs were higher in the D6 group (mean difference £276, 95% CI £225–£327) 227 
(Table 3) due to greater training costs but there were no differences in mean total health and 228 
social care costs (adjusted mean difference £150, 95% CI -£34–£333) or QALY gains at 18 229 
months (Appendix 4). 230 
Table 3 here 231 
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The inter-rater reliability for the MITI global domains of spirit and empathy was 0.87 and 232 
0.91 respectively so we combined both sets of ratings and derived the mean score for each 233 
domain. We rated 69 sessions (4.0% of all available recordings) for fidelity from 33/170 and 234 
36/164 patients from the D6 and standard care groups respectively (Table 4). The level of 235 
competency in the D6 group was below the beginner proficiency level in all the scales for MI 236 
and BECCI. Except for a slightly higher proportion of open questions in D6, and a slightly 237 
larger reflection/question ratio in standard care, there were no statistically significant 238 
differences in the remaining mean MI domain scores or BECCI scores.  239 
Table 4 here 240 
There were 43 serious adverse events (cardiovascular (n=11), injury (n=5), cancer (n=4), 241 
infection (n=5), diabetes-related (n=3), psychiatric (n=2), and other (n=10)), reported after 18 242 
months for 38 different participants (D6 n=14; standard care n=24) and 2 deaths from cancer, 243 
with no difference between the two groups 244 
Discussion 245 
Summary  246 
Training nurses in MI and basic CBT to support self-management did not lead to 247 
improvements in glycaemic control, or any other secondary outcomes, in people with T2D 248 
and persistent hyperglycaemia compared to attention control at 18 months from 249 
randomisation. Further, it was unlikely to be cost-effective. 250 
Strengths and limitations 251 
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This was a pragmatic design set in real-world, inner-city, primary care representing the ethnic 252 
and social diversity of people with T2D.27 Only a few other RCTs have achieved similar 253 
ethnicity distributions.28–34 This was a high risk group for diabetes complications. We 254 
selected a cluster design to reduce contamination of the intervention in the control group. 255 
Contamination is the process whereby an intervention intended for members of the trial 256 
(intervention or treatment) arm of a study is received by members of another (control) arm 257 
leading to a risk of under estimation of the effect.35 We assessed contamination by comparing 258 
the competencies in the intervention and control group. The hypothesis was that the control 259 
group would have lower competencies than the D6 group. As both groups had similar and 260 
borderline beginner proficiency competencies (which is probably the pre-training level of 261 
competency) we concluded it was unlikely there was contamination. We developed a 262 
theoretically informed intervention and an evidence-based manual. We measured fidelity 263 
(which is the same measure as competency in this study) to the intervention. We controlled 264 
for the non-specific effect of receiving more attention by D6 by offering similar number of 265 
sessions to patients randomised to the control group. We were only slightly underpowered at 266 
77% power compared to the 80% originally proposed. The upper limit of the 95% confidence 267 
interval of the estimated treatment effect for HbA1c (4.8 mmol/mol) was less than estimated 268 
treatment reductions in meta-analyses.36 The comprehensive within-trial economic evaluation 269 
assessed all relevant health and social care costs.  270 
The limitations of D6 included a 20% uptake of practice participation, despite the offer of 271 
generous backfill payments. The main reasons given by the practices when feedback was 272 
informally asked were the pressures to deliver current services with limited resources 273 
exacerbated by co-incidental national restructuring of primary care services creating 274 
organisational uncertainty. Data missingness for the economic analyses was high, however, 275 
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imputing missing data confirmed the lack of cost-effectiveness of D6. We did not obtain 276 
sufficient repeated measures of HbA1c. We failed to achieve a minimum level of beginner 277 
proficiency in motivational interviewing in the D6 group therefore unable to conclude that 278 
motivational interviewing is not effective in supporting self-management. 279 
Comparison with existing literature 280 
Although there have been over 40 RCTs in this field since the last review,36 only three had 281 
defined poor glycaemic control (HbA1c ≥64 mmol/mol) as an inclusion criterion and showed 282 
no benefit from psychological support andonly one of these was delivered by nurse care 283 
managers.37–39 Recent pragmatic RCTs of similar interventions included samples with near 284 
optimal glycaemic control with less room for improvement in the primary outcome.10,11,40 285 
Our sample had sustained high HbA1c so we may have selected a more severe group not 286 
suitable for practitioners with lower levels of psychological skill competencies.28–34  287 
We are one of a handful of RCTs to include fidelity and competency (a complex, laborious, 288 
and expensive process evaluation).41,42 On average patients attended only 50% of sessions in 289 
either group. This is a common observation in psychological interventions.43 However, no 290 
dose-response relationship was observed.  291 
Implications for research and/or practice 292 
There are several potential nurse, patient and methodological reasons for the non-significant 293 
effect of D6. The nurses did not self-select and may not have had the generic psychotherapist 294 
factors often attributed as the active ingredients in psychological treatments.44 D6 nurses had 295 
concerns about over-stepping their professional roles, lacking confidence, and/or resented the 296 
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extra workload. 45 The low competencies in most MI and CBT domains suggest that practice 297 
nurses may need longer periods of training or should self-select for generic psychotherapist 298 
skills in advance. Our findings may also reflect the difficulty of engaging this high risk 299 
clinical group but with low levels of worry. Even offering more nurse support in the form of 300 
more frequent sessions did not lead to improved glycaemic control. In exit interviews, 301 
patients stated they lacked time (although the majority was not employed) and difficulties in 302 
establishing a rapport with the nurses as reasons for dropout (unpublished observations). One 303 
methodological explanation is that we selected HbA1c, strongly associated to the levels of 304 
glycaemia, as a surrogate outcome for diabetes complications. However, a landmark RCT46 305 
and a meta-analysis of RCTs47 aimed at intensive glycaemic control have failed to observe 306 
consistently a positive effect on reduction of complications of diabetes or global mortality 307 
and there may be even a negative effect of increased mortality when tight glycaemic control 308 
is the aim. Perhaps these negative findings represent an opportunity to focus on psychological 309 
interventions to improve other outcomes such as blood pressure, lipids or a composite 310 
outcome.  Another methodological implication is whether the duration of the intervention and 311 
the follow up was too short. Brief psychological interventions are designed to be exactly that, 312 
with the added advantage of being cheap and not too demanding on the patient. However, our 313 
patients had a long history of poor self-management and may have needed a longer duration 314 
of therapy. Whether longer therapy would be pragmatic to be funded as a RCT or in the NHS 315 
is to be debated and is showing promise for chronic depression.48  316 
The implication for clinical practice is that low-intensity psychological interventions 317 
delivered at low level of competencies may not be as effective in supporting self-318 
management in people with T2D and longstanding suboptimal glycaemic control as 319 
previously thought. 320 
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 321 
A conceptual dilemma is that theoretical frameworks for MI and CBT assume  that mental 322 
health conditions remit (alcohol problems, smoking, depression) and this assumption does not 323 
apply to T2D which progressively worsen.49  324 
We urgently need to reconsider what skills, what competencies, which workforce are the 325 
most effective in delivering psychological interventions to improve glycaemic control in 326 
people with T2D 50 before investing sparse funds into low intensity psychological treatments 327 
for improving glycaemic control in T2D.51  328 
329 
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Figures 552 
Figure 1. Diabetes 6 (D6) study flow chart 553 
554 
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Tables 555 
Table 1. Baseline characteristics of participants randomly assigned to receive D6 or standard care. 
Variable* D6  (n=164) 
Standard 
Care  
 (n=170) 
Total 
Age (years) 59.0 (11.1) 58.9 (11.4) 58.9 (11.2) 
Gender      
 Male 82 (50.0%) 81 (47.7%) 163 (48.8%) 
 Female 82 (50.0%) 89 (52.4%) 171 (51.2%) 
Ethnicity       
 White 60 (36.8%) 74 (43.8%) 134 (40.4%) 
 African/Caribbean 81 (49.7%) 62 (36.7%) 143 (43.1%) 
 Asian/Other 22 (13.5%) 33 (19.5%) 55 (16.6%) 
Relationship status       
 Married or Cohabiting 82 (50.3%) 89 (52.7%) 171 (51.5%) 
 Separated/Divorced/Widowed 52 (31.9%) 45 (26.6%) 97 (29.2%) 
 Single 29 (17.8%) 35 (20.7%) 64 (19.3%) 
Education level       
 A-level or higher 47 (29.2%) 43 (25.8%) 90 (27.4%) 
 O-level or GCSE equivalent 68 (42.2%) 48 (28.7%) 116 (35.4%) 
 No formal qualifications 46 (28.6%) 76 (45.5%) 122 (37.2%) 
Employment       
 Yes1 69 (42.1%) 70 (41.2%) 139 (41.6%) 
 No2 95 (57.9%) 100 (58.8%) 195 (58.4%) 
Borough      
 Lambeth 83 (50.6%) 42 (24.7%) 125 (37.4%) 
 Southwark 25 (15.2%) 40 (23.5%) 65 (19.5%) 
 Lewisham 19 (11.6%) 52 (30.6%) 71 (21.3%) 
 Wandsworth 37 (22.6%) 24 (14.1%) 61 (18.3%) 
 Bexley 0 (0.0%) 12 (7.1%) 12 (3.6%) 
Diabetes duration (years) 10 (7–13) 9 (5–12) 9 (6–12) 
HbA1c (mmol/mol) 81.0 (17.1) 80.1 (19.1) 80.5 (18.1) 
Body mass index (kg/m2) 32.0 (5.6) 31.9 (6.6) 31.9 (6.1) 
Systolic blood pressure (mm/Hg) 135.2 (16.9) 133.2 (17.3) 134.2 (17.1) 
Diastolic blood pressure (mm/Hg) 79.5 (9.8) 79.0 (10.3) 79.2 (10.1) 
Total cholesterol (mmol/L) 4.3 (1.1) 4.2 (1.2) 4.2 (1.2) 
Fasting triglycerides (mmol/L) 1.7 (1.2) 1.7 (1.3) 1.7 (1.3) 
Taking insulin      
 Yes 75 (46.3%) 66 (39.8%) 141 (43.0%) 
 No 87 (53.7%) 100 (60.3%) 187 (57.0%) 
Any retinopathy      
 Yes 59 (35.9%) 65 (38.2%) 124 (37.1%) 
 No 105 (64.0%) 105 (61.8%) 210 (62.9%) 
Albumin:Creatinine ratio      
30 
 
 Negative 65 (59.1%) 83 (69.8%) 148 (64.6%) 
 Positive 45 (40.9%) 36 (30.3%) 81 (35.4%) 
Protein:Creatinine ratio      
 Negative 33 (76.7%) 17 (77.3%) 50 (76.9%) 
 Positive 10 (23.3%) 5 (22.7%) 15 (23.1%) 
Foot ulcers      
 Yes 9 (5.6%) 12 (7.1%) 21 (6.4%) 
 No 152 (94.4%) 157 (92.9%) 309 (93.6%) 
Macrovascular disease       
 Yes 61 (37.2%) 55 (32.4%) 116 (34.7%) 
 No 103 (62.8%) 115 (67.7%) 218 (65.3%) 
Patient Health Questionnaire-9 score       
 ≥10 31 (20.4%) 35 (22.4%) 66 (21.4%) 
 <10 121 (79.6%) 121 (77.6%) 242 (78.6%) 
Diabetes Distress Scale (mean item score) 2.1 (1.7–2.7) 2.0 (1.6–2.7) 2.1 (1.6–2.7) 
Data are n (%), median (IQR), or mean (SD), as appropriate. 
1Yes = full-time, part-time, student or self-employed; 2No = retired/unemployed/not seeking 
employment 
*Values missing for age (n=1), ethnicity (n=2), relationship status (n=2), education level (n=6), 
diabetes duration (n=20), body mass index (n=5), systolic blood pressure (n=25), diastolic blood 
pressure (n=26), HbA1c (n=1), total cholesterol (n=53), fasting triglycerides (n=58), insulin (n=6), 
albumin:creatinine ratio (n=105), protein:creatinine ratio (n=269), foot ulcers (n=2), Patient Health 
Questionnaire-9 (n=26), diabetes distress scale (n=27). 
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 559 
Table 2. Results from primary and secondary outcomes. 
Outcome at 18 months 
Participants 
with baseline 
measurements 
Participants 
with 
measurements at 
18 months 
Estimated Mean Difference: 
D6 vs standard care (95% 
CI) 
Primary       
HbA1c (mol/mmol)* 332 231 -0.79 (-5.75–4.18) 
Secondary       
Body mass index (kg/m2)* 329 152 -0.08 (-1.12–0.97) 
Total cholesterol* 281 140 -0.08 (-0.42–0.27) 
Systolic blood pressure 
(mm/Hg)* 309 198 -1.35 (-6.85–4.14) 
Diastolic blood pressure 
(mm/Hg)* 308 198 1.22 (-1.87–4.32) 
Fasting triglycerides** 276 135 0.02 (-0.22–0.26) 
Patient Health Questionnaire-
9 Score*** 308 114 -0.18 (-1.30–0.94) 
*Estimates based on linear combination from linear mixed-effects model with fixed effects of time (15 or 18 
months), an interaction between time and randomisation group, randomisation phase, borough and baseline 
values of the outcome, a random effect for GP practice nurse clustering and with unstructured covariance 
matrix to account for dependency of repeated observations. 
**Estimates based on linear combination from linear mixed-effects model with fixed effects of time (15 
months or 18 months), an interaction between time and randomisation group, randomisation phase, borough 
and baseline values of the outcome, a random effect for GP practice nurse clustering and with independent 
covariance structure due to convergence issues when estimating non-zero covariances. 
***Collected at 18 months only. Estimates based on linear combination from  linear mixed model with fixed 
effects of randomisation phase, borough, baseline value and  random within-cluster effect of nurse with 
unstructured covariance matrix to account for dependency of repeated observations. 
D6=Diabetes 6 
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Table 3. Mean costs (for the previous 6 months, £ sterling, 2011/12 prices), SF-12-based utility scores and QALY 
gains at baseline and/or 18 months. 
Costs at baseline 
D6 Standard care 
UMD* 95% CI AMD** 95% CI* valid 
n 
Mea
n £ SD 
valid 
n 
Mea
n £ SD 
Health and social 
care costs 157 847 847 161 976 760 -129 -301–44 -96 -293–101 
Costs at 18 months 
Health and social 
care costs, 
excluding 
intervention, 
without discounting 
133 707 579 137 793 558 -85 -252–81 -71 -242–100 
Health and social 
costs, excluding 
intervention, with 
discounting 
133 684 560 137 766 540 -82 -243–78 -69 -234–96 
Intervention costs 121 451 99 139 167 100 285 240–329 276 225–327 
Health and social 
care costs, 
including 
intervention costs, 
with discounting for 
non-intervention 
costs  
92 1184 572 107 1025 573 159 -39–357 150 -34–333 
SF-12-based utility scores at baseline 
Utility 157 0.75 0.16 159 0.74 0.16 0.01 -0.03–0.04 0.01 -0.03–0.00 
SF-12-based utility scores and QALY gains at 18 months 
Utility 60 0.79 0.13 53 0.75 0.13 0.04 -0.01–0.08 0.01 -0.03–0.06 
QALY gain since 
baseline, without 
discounting 
58 1.15 0.20 48 1.11 0.18 0.03 -0.04–0.10 0.01 -0.03–0.05 
QALY gain since 
baseline, with 
discounting and 
interpolation to 
match 6-month 
period for cost data 
58 0.37 0.06 48 0.36 0.06 0.01 -0.01–0.03 0.00 -0.01–0.02 
SF-12 = Short Form 12; QALY = quality-adjusted life year; D6 = Diabetes 6; UMD=Unadjusted mean difference; 
AMD=adjusted mean difference. 
*Intervention minus control. Comparisons include clustering for nurse. 
**Intervention minus control. Cost comparisons account for clustering for nurse plus covariates for baseline cost, age, 
gender, marital status, ethnicity, duration of diabetes and baseline utility. QALY comparisons account for clustering for 
nurse plus covariates for age, gender, marital status, ethnicity, duration of diabetes and baseline utility. 
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Table 4. Group comparison for fidelity to MI and CBT. 
MI domaina D6 Standard care p-value* 
Global Spirit  3.23 (1.13) 2.87 (0.87) 0.14 
Global Empathy  3.00 (2.00–4.00) 2.50 (2.00–3.00) 0.19 
Proportion Complex 
Reflections 0.35 (0.20) 0.40 (0.17) 0.25 
Proportion Open Questions  0.36 (0.17) 0.25 (0.10) <0.01 
Reflection/Question Ratio  0.57 (0.47–0.72) 0.74 (0.53–1.19) 0.03 
Proportion Motivational 
Interviewing Adherent 0.58 (0.32) 0.54 (0.28) 0.51 
CBT skills       
BECCI score 1.33 (0.56) 1.12 (0.55) 0.12 
Data are mean (standard deviation), or median (interquartile range), as appropriate. 
MI=Motivational interviewing; CBT=Cognitive behavour therapy; D6=Diabets 6; BECCI=Behaviour 
Change Counselling Index. 
*Based on result of either a t-test or Mann-Whitney U-test. 
aThe MITI guidance indicates that to reach proficiency, a practitioner must achieve an average global spirit 
rating of 3.5, a reflection to question ratio of ≥1, ≥0.5 open questions relative to all questions, ≥0.4 complex 
reflections relative to all reflections, and ≥0.9 MI adherent. 
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 589 
1 Full description of the study’s methods 590 
 591 
Trial design 592 
D6 was a pragmatic parallel two-arm cluster RCT design for 18 months. Ethical approval was 593 
granted by the King’s College Hospital Research Ethics Committee (reference 09/H0808/97) 594 
and by the respective Primary Care Trusts (reference RDLSLBex 534 and 2010/403/W). 595 
Changes to the protocol were approved by the Trial Steering Committee and the Research 596 
Ethics Committee. All participants gave informed consent, including access to their medical 597 
records.  598 
All moderate-to-large GP practices (≥6000 patients registered) in the Lambeth, Southwark, 599 
Lewisham, Wandsworth, and Bexley Clinical Commissioning Groups, representing a resident 600 
population of 1.43 million in south London, UK, were invited to participate if they had a 601 
practice nurse delivering diabetes care. Practices were reimbursed £10k for seconding their 602 
nurse for one day/week for 15 months. We began recruiting patients after each practice 603 
consented to randomisation. The study was conducted in two phases as recruitment had 604 
slowed down significantly secondary to organisational uncertainties caused by the Health and 605 
Social Care Act 2012. This Act reorganised the UK’s National Health Service (NHS), 606 
dismantling current organisational structures and creating new ones for funding, 607 
management, accountability, and regulation.15  608 
Patients 609 
The target population was adults with T2D who had persistent suboptimal glycaemic control 610 
despite care pathways based on national guidance,17 therefore a group likely to have barriers 611 
to achieving optimal self-management. The study population was patients on diabetes 612 
registers of consenting practices. Using standardised search strategies, a list of potentially 613 
eligible patients based on the HbA1c (current and preceding 18 months) was generated by 614 
each practice and invited to participate. Three practices were eligible and willing to 615 
participate but did not have a nurse to second. A protocol change was made in Phase 2, which 616 
allowed a consenting practice without a nurse to amalgamate with an adjacent consenting 617 
practice which had a nurse, and each pair formed one cluster. The rationale was that the 618 
36 
 
patient catchment area was likely to be similar and that both practices used the same clinical 619 
guidance for diabetes care.  620 
Inclusion criteria were adults aged 18–79 years, duration of T2D for ≥2 years, persistent 621 
suboptimal glycaemic control defined as HbA1c ≥69.4 mmol/mol on two occasions (at least 622 
once in the preceding 18 months and at recruitment) while on at least two oral diabetes 623 
medications (metformin and one other), and/or requiring insulin therapy. The HbA1c was 624 
lowered to ≥64 mmol/mol in Phase 2 to increase recruitment. These lower cut-offs for HbA1c 625 
was selected to maximise the proportion of patients who could potentially benefit. The 626 
minimum requirement of being prescribed at least two classes of oral diabetes medications 627 
was to ensure that efforts to optimise and intensify medical care according to national 628 
guidance had been offered to the patient before randomisation. Exclusion criteria were: 629 
severe mental disorders; terminal illnesses and end-stage diabetes complications; morbid 630 
obesity with a BMI >40 kg/m2 in Phase 1, which was raised to >50 kg/m2 in Phase 2 to 631 
enhance recruitment; non-ambulatory as patients had to be able to attend the clinic; no 632 
phone/internet access; non-English-speaking as therapy was delivered in English; and 633 
currently receiving psychological treatments from elsewhere. Patients who had Patient Health 634 
Questionnaire-9 (PHQ-9) depressive scores >20 were excluded if they had psychotic 635 
depression or active suicidal ideation.16  636 
Randomisation 637 
Randomisation of practices (unit of cluster) was conducted after baseline data were collected 638 
by an independent statistician using a random number generator to assign equal numbers of 639 
practices to each arm at each phase. Allocation concealment was conducted by holding the 640 
randomisation list by an independent manager in password-locked computer. The trial 641 
manager was only able to reveal to themselves, and then to one D6 researcher, the allocation 642 
after entering the details of the practice.  643 
Randomisation of clusters was intended to take place after all the patients had been recruited 644 
but this was leading to unacceptable delays in training the nurses. Therefore, some patients 645 
were recruited after randomisation of clusters but remained blind to allocation until the 646 
interventions were offered in both groups. 647 
Procedures 648 
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Baseline measures 649 
Baselines measures were: age, gender, self-reported ethnicity, occupation, employment 650 
status, and smoking status. HbA1c was measured centrally (King’s College Hospital NHS 651 
Foundation Trust) by affinity chromatography (Primus Ultra2, Kansas City, USA) and 652 
reported in mmol/mol. Complication status was assessed before randomisaton by the research 653 
assistant as follows: neuropathic ulcer risk  was assessed by perception of 10g monofilament; 654 
retinopathy coding e was taken from the most recent of annual standardised digital retinal 655 
photography documented in the community-based Diabetic Eye Complications Screening 656 
Service (DECS), with a new appointment arranged if one had been missed; urine was 657 
collected to assess nephropathy using the urinary albumin:creatinine ratio (ACR); and history 658 
of macrovascular complications collected from the medical records.  659 
In addition, the following secondary outcomes were measured: systolic and diastolic blood 660 
pressure using an electronic sphygmomanometer; body mass index (BMI) (kg/m2) and waist 661 
circumference (cm); depressive symptoms using the Patient Health Questionnaire-9 662 
questionnaire;16 the Alcohol Use Disorders Identification Test (AUDIT);23 and the Diabetes 663 
Distress Scale, which measures diabetes specific psychological burden (in the protocol we 664 
had proposed a similar but longer scale).24 A fasting blood sample was sent for measurement 665 
of HbA1c, total cholesterol, and triglycerides. 666 
Intervention 667 
Group 1: Standard care 668 
The nurse delivered diabetes care in both groups as recommended by national guidance.17 To 669 
control for attention, standard care nurses offered the same number of sessions as in D6. The 670 
sessions were audio-taped for assessment of contamination bias. 671 
Group 2: Standard care plus D6  672 
D6 aimed to provide the nurses with skills based on MI and CBT to address psychological 673 
barriers maintaining poor self-management. The theory underlying MI is that the patient’s 674 
state of ambivalence (resistance versus willingness to make lifestyle changes) is the core 675 
psychological construct that needs addressing.6 MI is a directive, person-centered counselling 676 
style which encourages patients to change behaviours using collaborative, non-judgmental, 677 
and affirming communications. The theory underlying CBT is that barriers to diabetes self-678 
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management are maintained by unhelpful thoughts (e.g., if I can’t cure diabetes, what’s the 679 
point?), unhelpful behaviours (e.g., missing insulin doses), and distressing emotions (e.g., 680 
low mood/anxiety when seeing a high blood glucose reading).18,19 Identifying and 681 
challenging these cognitive barriers are effective in changing behaviours.20  682 
The D6 nurses were trained in six skills drawn from MI and CBT: 1. Active listening; 2. 683 
Managing resistance; 3. Directing change; 4. Supporting self-efficacy; 5. Addressing health 684 
beliefs; and, 6. Shaping behaviours. These skills were applied to common barriers around 685 
diabetes such as medication adherence, self-testing, physical activity and dietary changes. 686 
The training was conducted by a senior diabetes-experienced clinical psychologist and lasted 687 
three months. It comprised three hours per week, interactive classroom activities, a training 688 
caseload (average 3-5 non-study patients), and weekly supervision of audiotaped sessions. 689 
We produced a manual containing the rationale for D6, the six psychological skills, case 690 
examples, strategies to manage clinician’s own resistance, and for ‘troubleshooting’ common 691 
clinical obstacles. D6 nurses were expected to apply the skills flexibly to different situations 692 
(e.g., weight loss, medication adherence) using visual aids and worksheets. The format was 693 
12 face-to-face individual sessions (sessions 1-4 fortnightly during months 1-2, sessions 5-6 694 
monthly during months 3-6, and sessions 7-12 during months 7-12). Monthly group 695 
supervision by a senior clinical psychologist was provided. The sessions were audio-taped for 696 
assessment of fidelity.  697 
The Motivational Interviewing Treatment Integrity (MITI) Scale (version 3.1.1)21 and 698 
Behaviour Change Counselling Index (BECCI)22 were used to assess treatment fidelity of D6, 699 
and to compare competencies in both groups. The MITI assesses: global spirit and global 700 
empathy with scores ≥ 3.5 (range 1-5); percentage of complex reflections, open questions, 701 
and MI adherent behaviours with scores of ≥40%, 50%, and 90% respectively; and ratio of 702 
reflections to closed questions scores with ≥1 as proficient. The middle 20 minutes of 703 
sessions were rated by two independent psychologists trained in MITI and blind to treatment 704 
allocation. The BECCI consists of 11 items with 5-point Likert scales to rate the frequency or 705 
the strength of the nurse skill, ranging from 0 (not at all) to 4 (a great extent). A clinical 706 
psychologist, blind to treatment allocation, rated the BECCI. We stratified sessions by nurse 707 
and patient and then randomly selected tapes (that lasted ≥20 minutes) for 3 different patients 708 
for each nurse from either session 2, 3 and 4. Three nurses did not have three tapes lasting 20 709 
minutes or more and, for these, the three longest tapes were chosen.  710 
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Outcomes 711 
As the recruitment and follow-up was delayed by the NHS restructuring and patient attrition, 712 
the protocol was changed from 24 months follow-up to 18 months. The primary outcome was 713 
change in HbA1c from cluster randomisation to 18 months. If the study HbA1c data were 714 
missing at 18-month, we used routinely collected HbA1c data if it was collected within the 715 
15-month follow-up window. Secondary outcomes were change in lipids, blood pressure, 716 
BMI and depressive symptoms at 18 months. Research assistants were blind to allocation 717 
when collecting follow-up data. 718 
Sample size 719 
A 10.9 mmol/mol difference in HbA1c in D6 compared to standard care was the minimal 720 
clinically acceptable reduction at 18 months, considering: (a) baseline HbA1c and (b) that 721 
standard care may produce a 2.2 mmol/mol (equivalent to 0.2%) reduction in HbA1c for the 722 
placebo effect of participating in a RCT (actual difference between groups 8.8 mmol/mol 723 
(equivalent to 0.8%), equivalent to a moderate effect size of d=0.55). Assuming 20% 724 
dropout, we needed 360 patients to achieve 80% power at a two-sided alpha-level of 5%, 725 
with 20 practices with 18 patients each per arm. We then took account of clustering by 726 
practice and we assumed two practices per arm dropped out. Therefore, we needed 24 727 
practices with a total patient size of 24x18=432 patients. The required sample size adjusted 728 
for a clustering intra-correlation coefficient (ICC) effect of 0.05 was 81x1.7=138 patients per 729 
arm (inflation factor 1.7).  730 
We recruited 334 patients of which 231 had at least one follow-up in 24 clusters. The average 731 
cluster size was therefore 10 patients per cluster, smaller than our assumed size of 15 patients 732 
per cluster with a post-hoc power of 77% (STATA 13 clsampsi function) at two-sided alpha-733 
level of 5%.25 734 
Statistical analysis 735 
Data were analysed using STATA 13. The sample characteristics were described as means 736 
(standard deviation (SD)) or as proportions (percentage). A comparison of patient list size 737 
and Index of Multiple Deprivation rank score by practices that participated versus those that 738 
did not was conducted using Student’s t-test.26 A linear mixed-effects model estimated group 739 
differences in HbA1c levels between D6 and standard care groups at 18 months. We included 740 
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the 15-month HbA1c as this clinically just overlaps with the 3-month window for 18-month 741 
HbA1c and to include more patients with at least one follow-up measure. Data were analysed 742 
as intention-to-treat (ITT). Time (with two levels: 15 and 18 months), treatment group, an 743 
interaction between treatment group and time, Primary Care Trust (as a possible prognostic 744 
factor), recruitment phase, and baseline HbA1c were included as fixed covariates. The 745 
dependency of the repeated observations of the same subjects was modeled on the covariance 746 
between the residuals using an unstructured covariance pattern model. Nurse was included as 747 
a random effect as the unit of randomisation.  748 
Observations from the same nurse cluster were likely to be more similar than observations 749 
from two different clusters. However, in three cases, a practice was twinned with an adjacent 750 
practice and one nurse covered both practices. Therefore, two types of clustering could occur: 751 
within practice and within nurse. We assumed that nurse clustering would have a stronger 752 
effect than practice clustering. We therefore treated the twinned practices as one unit which is 753 
equivalent to treating nurse as the primary clustering unit. However, we repeated the model 754 
using ‘practice’ as the main clustering unit in a sensitivity analysis.  755 
Secondary outcomes were analysed in the same way using linear mixed models to estimate 756 
group differences at 18 months (including15 months). An independent covariance structure 757 
pattern was used for the triglycerides as the model did not converge using unstructured 758 
covariance.  759 
Twenty-nine participants with HbA1c <64 mmol/mol contrary to the study criteria were 760 
included and this was a protocol violation. We performed a sensitivity analysis by including a 761 
binary covariate of this protocol violation (yes/no) in the model.  762 
The analyses were conducted using maximum likelihood under the missing at random 763 
assumption. Sensitivity analyses were carried out to assess sensitivity to missingness in 764 
HbA1c using several approaches: by investigating and including predictors of missingness in 765 
the model and by using multiple imputation for the missing values of HbA1c (50 imputations 766 
using mi impute command in STATA 13 with all variables from the mixed-effects model 767 
included in the imputation model, as well as age, ethnicity, gender, baseline BMI, total 768 
cholesterol, triglycerides, blood pressure, and PHQ-9 score).  769 
The Data Monitoring Committee oversaw the study.  770 
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Fidelity 771 
To assess IRR for each fidelity measure, absolute agreement was measured by estimating the 772 
ICC from a two-way mixed model or using Spearman’s rank correlation coefficient if 773 
residuals from the mixed model were not normally distributed. A t-test or Mann-Whitney U-774 
test was used to compare the skills of D6 versus standard care nurses, using STATA 14.  775 
Role of funding source 776 
The funder of the study had no role in study design, data collection, data analysis, data 777 
interpretation, or reporting. The authors had full access to all data and final responsibility for 778 
submission for publication and acted independently from the funding source.  779 
Patient Involvement 780 
We included a person with type 1 diabetes from our local community who also was an active 781 
member of the local and national Diabetes UK.  This person was instrumental in guiding us 782 
to use NHS practice nurses rather than research diabetes nurses to deliver the intervention. 783 
This person inputted into the importance of quality of life and psychological well-being as 784 
outcome measures alongside glycaemic control. For the process evaluation, we invited 785 
participants to give us feedback of the intervention in terms of the perception of burden as 786 
patients. We included a person with type 1 diabetes on the Trial Steering Committee. 787 
Transparency Declaration 788 
The lead author affirms that the manuscript is an honest, accurate, and transparent account of 789 
the study being reported; that no important aspects of the study have been omitted; there were 790 
discrepancies from the study as planned and these have been explained. 791 
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2 Additional Tables 792 
 793 
Table 1. Breakdown of patients attending each practice and primary outcome follow-up 
rates by group. 
D6 Standard care 
Practice*  
Proportion with 
HbA1c data at 18 
months (%) 
Practice*  
Proportion with 
HbA1c data at 18 
months (%) 
1 14/18 (77.8)  2 11/12 (91.7)  
3 13/19 (72.2)  4 14/19 (73.7)  
5 7/16(64.3)  6 11/18 (61.1)  
7 6/9 (66.7)  8 12/17 (70.6)  
9 15/16 (93.8)  10 6/12 (50.0)  
11 6/12 (50.0)  12 13/13 (100.0)  
13 6/9 (66.7)  14 13/17 (76.5)  
15** 9/18 (50.0)  16 13/17 (76.5)  
17 9/13 (69.2)  18 5/8 (62.5)  
19** 12/14 (85.7)  20*** 1/4 (25.0)  
21 8/14 (57.1)  22 5/11 (45.5)  
23** 4/12 (33.3)  24 6/16 (37.5) 
Total 109/170 (64.1%) Total 110/164 (67.1%)  
* Practices 1-6 are from Phase 1 (HbA1c ≥ 69.4 mmol/mol and BMI ≤ 40kg/m2). Practices 7-
24 are from Phase 2 (HbA1c ≥ 64 mmol/mol, BMI ≤ 50kg/m2, and twinned practices). 
** Two practices twinned and covered by 1 nurse. 
*** Practice dropped out post-randomisation. 
D6=Diabetes 6 
 794 
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 796 
Table 2. Comparison of missingness in HbA1c at 18 months. 
Variable HbA1c measured at 18 months (n=219) 
Missing HbA1c 
at 18 months 
(n=115) 
Test of 
independence (t-test 
or Pearson χ2-test) 
Age (years) 58·9 (11·4) 59·0 (11·0) t=0·045, p=0·964 
Ethnicity    
χ2(3)=14·854, 
p=0·001 
 White 72 (33·0) 62 (54·4) 
 African/Caribbean 103 (47·3) 40 (35·1) 
 Asian/Other 43 (19·7) 12 (10·5) 
Gender    
χ 2(1)=0·439, p=0·507  Male 104 (47·5) 59 (51·3) 
 Female 115 (52·5) 56 (48·7) 
Education level   
χ 2(2)=0·091, p=0·956 
 A levels or higher 60 (27·9) 30 (26·6) 
 O level or GCSE equivalent 75 (34·9) 41 (36·3) 
 No formal qualifications 80 (37·2) 42 (37·2) 
Relationship status    
χ 2(2)=1·221, p=0·543 
 Married or Cohabiting 112 (51·3) 59 (51·3) 
 Separated/Divorced/Widowed 60 (27·7) 37 (32·2) 
 Single 45 (20·7) 19 (16·5) 
Employment   
χ 2(1)=0·040, p=0·841  Yes 92 (42·0) 47 (40·9) 
 No 127 (58·0) 68 (59·1)  
BMI (kg/m2) 32·1 (6·0) 31·5 (6·4) t=-0·839, p=0·402 
Systolic BP  (mm/Hg) 133·6 (17·2) 135·3 (16·9) t=-0·823, p=0·411 
Diastolic BP (mm/Hg) 79·2 (10·0) 79·2 (10·3) t=-0·052, p=0·958 
HbA1c  (mmol/mol) 79·1 (17·4) 83·2 (19·3) t=-1·96, p=0·051 
Total Cholesterol (mmol/L) 4·2 (1·1) 4·3 (1·3) t=-0.501, p=0.617 
Fasting triglycerides (mmol/L) 1·6 (1·2) 1·9 (1·4) t=-1.631, p=0.104 
Diabetes duration (years) 10·5 (6·1) 10·0 (6·7) t=-0.694, p=0.488 
DDS (mean item score) 2·2 (0·8) 2·3 (0·8) t=0.959, p=0.338 
Data are n (%) or mean (SD), as appropriate. 
1 Yes = full time, part-time, student or self-employed 
2 No = retired/unemployed/not seeking employment 
BMI = Body mass index; BP = blood pressure; DDS = Diabetes Distress Scale 
797 
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 798 
Table 3. Inter-rater reliability for each MI domain. 
 MI Domain Inter-rater reliability* 
Global Spirit (ICC) 0·87 
Global Empathy (Spearman’s rho) 0·91 
% Complex Reflections (ICC) 0·86 
% Open Questions (ICC) 0·92 
Reflection/Question Ratio 
(Spearman’s rho) 0·88 
% MI Adherent (ICC) 0·90 
MI=Motivational interviewing; ICC=Intra-class correlation coefficient 
*Reliability was calculated as an ICC if the distribution was normal and a 
Spearman’s rho if non-normal. 
 799 
We rated 69 sessions (4.0% of all available recordings) for fidelity from 33/170 and 36/164 800 
patients from the D6 and standard care groups, respectively. The level of competency in the 801 
D6 group was below the beginner proficiency level in all the scales for MI and BECCI. 802 
Except for a slightly higher proportion of open questions in D6, and a slightly larger 803 
reflection/question ratio in standard care, there were no statistically significant differences in 804 
the remaining mean MI domain scores or BECCI scores.805 
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 809 
3 CONSORT 2010 checklist of information for reporting a cluster randomised 810 
trial 811 
Section/Topic Item 
No 
Standard Checklist item Extension for 
cluster designs 
Page 
No * 
Title and abstract  
 1a Identification as a 
randomised trial in the title 
Identification as a cluster 
randomised trial in the title 
1 
1b Structured summary of 
trial design, methods, 
results, and conclusions 
(for specific guidance see 
CONSORT for abstracts)i,ii 
See table 2 2 
Introduction  
Background and 
objectives 
2a Scientific background and 
explanation of rationale 
Rationale for using a cluster 
design 
4-5 
2b Specific objectives or 
hypotheses 
Whether objectives pertain to 
the the cluster level, the 
individual participant level or 
both 
4 
Methods  
Trial design 3a Description of trial design 
(such as parallel, factorial) 
including allocation ratio 
Definition of cluster and 
description of how the design 
features apply to the clusters 
5-6 
3b Important changes to 
methods after trial 
commencement (such as 
eligibility criteria), with 
reasons 
 Appendix 
Participants 4a Eligibility criteria for 
participants 
Eligibility criteria for clusters  5 
4b Settings and locations 
where the data were 
collected 
 5 
Interventions 5 The interventions for each 
group with sufficient 
details to allow replication, 
including how and when 
they were actually 
administered 
Whether interventions pertain 
to the cluster level, the 
individual participant level or 
both 
6-7 
Outcomes 6a Completely defined pre-
specified primary and 
secondary outcome 
measures, including how 
and when they were 
assessed 
Whether outcome measures 
pertain to the cluster level, the 
individual participant level or 
both 
7-8 
6b Any changes to trial 
outcomes after the trial 
commenced, with reasons 
 7-8, Appendix 
Sample size 7a How sample size was 
determined 
Method of calculation, number 
of clusters(s) (and whether 
equal or unequal cluster sizes 
are assumed), cluster size, a 
coefficient of intracluster 
correlation (ICC or k), and an 
indication of its uncertainty 
8, Appendix 
7b When applicable,  NA 
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explanation of any interim 
analyses and stopping 
guidelines 
Randomisation:  
 Sequence 
generation 
8a Method used to generate 
the random allocation 
sequence 
 6, Appendix 
8b Type of randomisation; 
details of any restriction 
(such as blocking and block 
size) 
Details of stratification or 
matching if used 
6, Appendix 
 Allocation 
concealment 
mechanism 
9 Mechanism used to 
implement the random 
allocation sequence (such 
as sequentially numbered 
containers), describing any 
steps taken to conceal the 
sequence until 
interventions were 
assigned 
Specification that allocation was 
based on clusters rather than 
individuals and whether 
allocation concealment (if any) 
was at the cluster level, the 
individual participant level or 
both 
6, Appendix 
 Implementation 
 
10 Who generated the random 
allocation sequence, who 
enrolled participants, and 
who assigned participants 
to interventions 
Replace by 10a, 10b and 10c  
 10a  Who generated the random 
allocation sequence, who 
enrolled clusters, and who 
assigned clusters to 
interventions 
 
6, Appendix 
 10b  Mechanism by which individual 
participants were included in 
clusters for the purposes of the 
trial (such as complete 
enumeration, random sampling) 
6, Appendix 
 10c  From whom consent was sought 
(representatives of the cluster, 
or individual cluster members, 
or both), and whether consent 
was sought before or after 
randomisation 
 
5-6,18, 
Appendix 
     
Blinding 11a If done, who was blinded 
after assignment to 
interventions (for example, 
participants, care 
providers, those assessing 
outcomes) and how 
 8 
11b If relevant, description of 
the similarity of 
interventions 
 6-7 
Statistical 
methods 
12a Statistical methods used to 
compare groups for 
primary and secondary 
outcomes 
How clustering was taken into 
account 
8-9, Appendix 
12b Methods for additional 
analyses, such as subgroup 
analyses and adjusted 
analyses 
 8-9, Appendix 
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Results  
Participant flow 
(a diagram is 
strongly 
recommended) 
13a For each group, the 
numbers of participants 
who were randomly 
assigned, received intended 
treatment, and were 
analysed for the primary 
outcome 
For each group, the numbers of 
clusters that were randomly 
assigned, received intended 
treatment, and were analysed 
for the primary outcome 
9-10, Figure 1, 
Appendix 3 
Table 1 
13b For each group, losses and 
exclusions after 
randomisation, together 
with reasons 
For each group, losses and 
exclusions for both clusters and 
individual cluster members 
9-10, Figure 1, 
Appendix 3 
Table 1 
Recruitment 14a Dates defining the periods 
of recruitment and follow-
up 
 Figure 1, 
Appendix 
14b Why the trial ended or was 
stopped 
 NA 
Baseline data 15 A table showing baseline 
demographic and clinical 
characteristics for each 
group 
Baseline characteristics for the 
individual and cluster levels as 
applicable for each group 
Table 1 
Numbers 
analysed 
16 For each group, number of 
participants (denominator) 
included in each analysis 
and whether the analysis 
was by original assigned 
groups 
For each group, number of 
clusters included in each 
analysis 
10, Figure 1 
Outcomes and 
estimation 
17a For each primary and 
secondary outcome, results 
for each group, and the 
estimated effect size and its 
precision (such as 95% 
confidence interval) 
Results at the individual or 
cluster level as applicable and a 
coefficient of intracluster 
correlation (ICC or k) for each 
primary outcome 
10-11 
17b For binary outcomes, 
presentation of both 
absolute and relative effect 
sizes is recommended 
 NA 
Ancillary 
analyses 
18 Results of any other 
analyses performed, 
including subgroup 
analyses and adjusted 
analyses, distinguishing 
pre-specified from 
exploratory 
 10-11, 
Appendix 
Harms 19 All important harms or 
unintended effects in each 
group (for specific guidance 
see CONSORT for harmsiii) 
 12 
Discussion  
Limitations 20 Trial limitations, 
addressing sources of 
potential bias, imprecision, 
and, if relevant, multiplicity 
of analyses 
 12-15 
Generalisability 21 Generalisability (external 
validity, applicability) of 
the trial findings 
Generalisability to clusters 
and/or individual participants 
(as relevant) 
12-15 
Interpretation 22 Interpretation consistent 
with results, balancing 
benefits and harms, and 
considering other relevant 
 12-15 
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evidence 
Other information   
Registration 23 Registration number and 
name of trial registry 
 2 
Protocol 24 Where the full trial 
protocol can be accessed, if 
available 
 NA 
Funding 25 Sources of funding and 
other support (such as 
supply of drugs), role of 
funders 
 17 
* Note: page numbers optional depending on journal requirements 812 
813 
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4 Supplementary Data from the Economic Evaluation 815 
Correspondence to: Professor Anita Patel anitapatelconsulting@gmail.com 816 
4.1 Summary of methods 817 
 818 
A within-trial economic evaluation assessed the cost-effectiveness of D6 from a health and 819 
social care perspective at 18 months. This linked individual-level costs with HbA1c and 820 
quality-adjusted life year (QALY) gains estimated from the Short Form 12 (SF-12) version 821 
2.52,53 We calculated individual-level total costs (English pounds sterling, £, 2011–12 prices) 822 
by attaching unit costs from national sources to individual-level (all-cause) resource use 823 
quantities covering a retrospective 6-month period at baseline and 18 months. Use of hospital 824 
services was assessed by retrospective review of hospital records. Use of out-of-area hospital 825 
services, community-based services, and medications were measured by self-report using a 826 
specifically developed proforma. Cost estimates for D6 included the full costs of staff 827 
training/supervision/assessment and time spent on delivery to patients. Outcomes and costs at 828 
18 months were discounted by 3.5%. 829 
Costs and QALY gains at 18 months were compared using non-parametric bootstrap 830 
regressions (10000 repetitions) with baseline covariates and adjustment for nurse. We only 831 
calculated incremental cost-effectiveness ratios where either group showed statistically 832 
greater costs and outcomes. The probability of cost-effectiveness for D6 was assessed by 833 
constructing cost-effectiveness acceptability curves (10000 bootstrap repetitions) for 834 
threshold ranges of £0–£50,000 per QALY gain/point improvement in HbA1c. Sensitivity 835 
analyses explored the impact on cost and/or outcome differences when: (a) missing data due 836 
to loss of follow-up were imputed (using multiple imputation in STATA 11.2) rather than 837 
excluded, (b) the unit cost of the D6 intervention was lowered by assuming 50% more people 838 
received D6, (c) accounting for the inadvertent inclusion of 29 individuals with HbA1c <64 839 
mmol/mol by including a binary covariate for this, and (d) accounting for clustering at 840 
practice rather than nurse level.  841 
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4.2 Intervention Costs 842 
 843 
Table S1: D6 intervention costs (English pounds sterling, £, 2011–12 prices; total costs rounded to nearest £) 844 
Intervention 
Component 
Description Resources Resource and cost details Total cost Unit cost per 
participant (n164) 
Training One training session (three hours) per 
week for 12 weeks, for 11 trainees. 
Delivered by one clinical psychologist 
over two training courses. 
Trainer’s time 1 band 8a clinical psychologist for 4 hours (3 hour training plus 1 hour 
preparation) for 12 weeks for 2 courses (1 * 4 * 12 * 2 * £601) £5,760 
£20,074 £122 
Trainees’ time 11 trainees (primary care nurses) for 3 hours for 12 weeks (11 * 3 * 12 * 
£352) £13,860. 
Capital/materials Room to train in: 3 hours training for 12 weeks for 2 courses (3 * 12 * 2 * 
£3.10 per hour3) £223.20.  
Printing of 11 D6 psychology skills handbook: (11 * £11.944) £131.34. 
Printing of 10 A4 PowerPoint presentations for 12 session for 11 trainees 
(10 * 12 * 11 * £0.065) £79.20. 
Use of 1 video camera: £19.996 
Supervision Supervision for trainees provided in two 
hour group sessions by a clinical 
psychologist. 
 
Trainer’s time 1 band 8a clinical psychologist for 3 hours (2 hour supervision plus 1 hour 
preparation) for a total of 35 group supervision sessions (1 * 3 * 35 * £601) 
£6,300. 
1 band 8a clinical psychologist for 30 minutes for transcription of 131 
taped trainee sessions (0.5 * 131 * £601) £3,930. 
£23,449 £143 
Trainees’ time 1 trainee (primary care nurse) for 2 hours for 140 trainee attendances at 
group sessions (1 * 2 * 140 * £352) £9,800. 
Transcription Transcription of 131 30-minute sessions: (131 * 30 * 0.80) £3,1447. 
Materials 1 audio recorder per trainee: (11 * £24.998) £274.89. 
Assessment One 30-minute assessment by band 8a 
nurse per trainee 
Assessor’s time 1 band 8a nurse for 30-minutes, for 11 assessments (1 * 0.5 * 11 * £609) 
£330 
£330 £2 
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Total for training £43,853 £267 
Intervention Participants offered 12 sessions over 
twelve months. 
Trainees’ time Individually calculated for each case based on number of sessions attended 
(assume 30 minute session): (30 minutes * £0.75 per minute10) £22.50 per 
session. 
Cost per 
patient 
Mean £301 
Sources and details (all pounds sterling (£), 2011/12 prices): 
1. Curtis L. 2012. Unit Costs of Health and Social Care 2012. Personal Social Services Research Unit: University of Kent. Based on £60 per hour, band 8a clinical 
psychologist. 
2. Curtis L. 2012. Unit Costs of Health and Social Care 2012. Personal Social Services Research Unit: University of Kent. Based on £35 per hour excluding qualifications. 
3. Hurley MV, Walsh NE, Mitchell HL, Pimm J, Williamson E, Jones RH, Reeves BC, Dieppe PA, Patel A. Economic evaluation of a rehabilitation program integrating 
exercise, self-management, and active coping strategies for chronic knee pain. Arthritis & Rheumatism (Arthritis Care & Research) 2007; 57 (7): 1220-122. Obtained further 
details via correspondence with the authors. Based on capital costs of a gym (£5.10 per hour, 2003/4 prices), halved to give more appropriate sized room (£2.55), inflated to 
2011/12 prices (£3.10), (inflation source: Curtis L. 2012. Unit Costs of Health and Social Care 2012. Personal Social Services Research Unit: University of Kent, The 
Hospital & Community Health Services (HCHS) index – annual percentage prices increase). 
4. Information from the clinical team: £11.94 each.  
5. Rymans photocopying. Available at: http://www.ryman.co.uk/photocopying [accessed: 13/02/2015]: £0.06 per copy for 100+ pages 
6. Argos camcorder. Available at: http://www.argos.co.uk/static/Product/partNumber/2268077.htm [accessed: 13/02/2015]: £19.99 for the lowest priced camcorder. 
7. Transcript Divas Transcription Services. Available at: http://transcriptdivas.co.uk/ [accessed: 13/02/15] Based on £0.80 per minute of recording data. 
8. Argos voice recorder. Available at: http://www.argos.co.uk/static/Product/partNumber/3071452.htm [accessed: 13/02/2015]: £24.99 for the lowest priced voice recorder. 
9. Curtis L. 2012. Unit Costs of Health and Social Care 2012. Personal Social Services Research Unit: University of Kent. Based on £46,600 median full-time equivalent total 
earnings for a band 8a nurse, with proportions of a band 7 nurse for per hour cost applied (£40,200 - £52 per hour): £60 per hour. 
10. Curtis L. 2012. Unit Costs of Health and Social Care 2012. Personal Social Services Research Unit: University of Kent. Based on £45 per hour of face-to-face contact 
excluding qualifications.  
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4.3 Other Unit Costs 846 
Table S2: Unit costs 847 
Item Unit Unit 
cost (£) 
2011-12 
prices 
Sourc
e 
Notes 
     
Inpatient services     
Nervous System bed day 368 1 NHS reference cost - Code A 
Eyes & Periorbital bed day 606 1 NHS reference cost - Code B 
Mouth, head, neck & ears bed day 519 1 NHS reference cost - Code C 
Respiratory system bed day 326 1 NHS reference cost - Code D 
Cardiac Surgery & Primary Cardiac 
Conditions 
bed day 452 1 NHS reference cost - Code E 
Digestive System bed day 428 1 NHS reference cost - Code F 
Hepato-biliary and Pancreatic Systems bed day 398 1 NHS reference cost - Code G 
Musculoskeletal System bed day 486 1 NHS reference cost - Code H 
Skin, Breast & Burns bed day 404 1 NHS reference cost - Code J 
Endocrine & Metabolic System bed day 327 1 NHS reference cost - Code K 
Urinary Tract & Male Reproductive Systems bed day 350 1 NHS reference cost - Code L 
Female Reproductive System & Assisted 
Reproduction 
bed day 599 1 NHS reference cost - Code M 
Obstetrics bed day 818 1 NHS reference cost - Code N 
Diseases of Childhood & Neonates bed day 577 1 NHS reference cost - Code P 
Vascular System bed day 472 1 NHS reference cost - Code Q 
Radiology and Nuclear Medicine bed day 513 1 NHS reference cost - Code R 
Haematology, Chemotherapy, Radiotherapy & 
Specialist Palliative Care 
bed day 448 1 NHS reference cost - Code S 
Multiple Trauma, Emergency Medicine and 
Rehabilitation 
bed day 458 1 NHS reference cost - Code T 
Immunology, Infectious Diseases & other 
contacts 
bed day 360 1 NHS reference cost - Code W 
General inpatient bed day 439 1 NHS reference cost - Overall inpatient 
A&E bed day 112 1 TAandEMSNA - Accident and Emergency 
Services: Not Leading to Admitted 
     
Outpatient services     
Diabetes clinic visit 134 1 307 - diabetic medicine on Total-OPATT tab 
Diabetes foot clinic visit 134 1 cost as diabetes clinic 
Diabetes eye clinic visit 134 1 cost as diabetes clinic 
Ophthalmology visit 86 1 130 - ophthalmology on Total-OPATT tab 
Blood tests / phlebotomy visit 3 1 DAP839 - Phlebotomy: on TDAPS tab (Pathology 
services) 
Dietetics visit 57 1 Total - OPATT Tab: Service code 654A - Adult 
dietetics 
General medical outpatient visit 158 1 300 - general medicine on Total-OPATT tab 
Day surgery centre visit 123 1 Total OPATT (Outpatient Attendances Data) tab -  
code 100 - general surgery 
A&E visit 110 1 180 - A&E on Total-OPATT tab 
X-ray (x-ray only) visit 30 1 Total - OPATT Tab: Direct Access Plain Film - 
DAPF 
     
Community based professionals     
GP at surgery contact 36 2 P183 - PSSRU - per patient contact lasting 11.7 
minutes - Excludes qualification costs, including 
direct care staff costs. 
GP at home contact 92 2 P183 - PSSRU - per patient out of surgery visit 
lasting 23.4 minutes - Excludes qualification costs, 
including direct care staff costs. 
GP telephone contact 22 2 P183 - PSSRU - per telephone contact lasting 7.2 
minutes - Excludes qualification costs, including 
direct care staff costs. 
Diabetes specialist nurse at surgery contact 11.11 2 p178 - PSSRU - Nurse specialist - £43 per hour 
excluding qualifications, assuming 15.5 (specified 
on p180 for practice nurse) min appointment 
Diabetes specialist nurse at home contact 16.11 2 p178 - PSSRU - Nurse specialist - £43 per hour 
excluding qualifications,  - using per hour of home 
visiting from community nurse (p175) - £61:£42 = 
1.45 SO - 11.11*1.45=16.11 
Diabetes specialist nurse telephone contact 6.78 2 p178 - PSSRU - Nurse specialist - £43 per hour 
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excluding qualifications, assume same proportion of 
costs as a GP telephone call (61% (*0.61)) - 
11.11*.61=6.78 
Practice nurse at surgery contact 11.63 2 P180 - PSSRU - £45 per hour of face-to-face 
contact excluding qualifications assuming 15.5 
(specified on p180) min appointment 
Practice nurse at home contact 16.166 2 based on practice nurse surgery visit cost above but 
use the proportion of district nurse home visit hour / 
clinic hour proportion from PSSRU 2010 
(68/49=139%) 
Practice nurse telephone contact 7.0943 2 assume same proportion of costs as a GP telephone 
call (61% (*0.61)) 
Chiropodist/podiatrist at surgery contact 48.529 1 TOCS tab - N910 Podiatry services - £47 per 
activity 
Chiropodist/podiatrist at home contact 70.367 1 TOCS tab - N910 Podiatry services - £47 per 
activity - with proportions of home visit from 
community nurse (p175, PSSRU) - £61:£42 = 1.45 
SO - 47*1.45=68.15 
Chiropodist/podiatrist telephone contact 29.603 1 assume same proportion of costs as a GP telephone 
call (61% (*0.61)) 
Optician at surgery contact 20.7 3 "The fee paid to an optical contractor for carrying 
out an NHS sight test by the governments of 
England, Wales, and Northern Ireland remains at 
£20.70 for the year 1 April 2011 to 31 March 2012" 
Optician at home contact 28.773 2 based on surgery visit cost above but use the 
proportion of district nurse home visit hour / clinic 
hour proportion from PSSRU 2010 (68/49=139%) 
Optician telephone contact 12.627 2 assume same proportion of costs as a GP telephone 
call (61% (*0.61)) 
District nurse at surgery contact 11.347 2 based on district nurse home visit cost above but 
use the proportion of clinic hour / home visit hour 
proportion from PSSRU 2010 (49/68=72%) 
District nurse at home contact 15.76 2 P175 - PSSRU - Community nurse including 
district - £61 per hour of home visiting including 
travel, excluding quals, assume 15.5 (see page 180) 
min appointment 
District nurse telephone contact 9.6136 2 assume same proportion of costs as a GP telephone 
call (61% (*0.61)) 
Dietician at surgery contact 72.277 1 TOCS tab - N800 Dietetics services - £70 per 
activity 
Dietician at home contact 104.8 1 Cost combines price from 2011/12 (above) but with 
proportions of home visit from community nurse 
(p175, PSSRU) - £61:£42 = 1.45 SO - 
70*1.45=101.5 
Dietician telephone contact 44.089 1 assume same proportion of costs as a GP telephone 
call (61% (*0.61)) 
Physiotherapist at surgery contact 48.529 1 TCSCT tab (community based therapy services) - 
N5A1 - Community Physiotherapy Services : Adult 
- One-to-One Services - £47 
Physiotherapist at home contact 70.367 1 TCSCT tab (community based therapy services) - 
N5A1 - Community Physiotherapy Services : Adult 
- One-to-One Services - £47 - but with proportions 
of home visit from community nurse (p175, 
PSSRU) - £61:£42 = 1.45 SO - 47*1.45=68.15 
Physiotherapist telephone contact 29.603 1 assume same proportion of costs as a GP telephone 
call (61% (*0.61)) 
Occupational therapist at surgery contact 30 2 p168 - pssru - NHS community OT - £30 per hour - 
assume 1 hour meeting, Excludes qualification 
costs. 
Occupational therapist at home contact 54.78 2 Cost combines price from 2011/12 (above) but with 
proportions of client time set down in 2009-10 
(p152) book (£42 per home visit / £23 per hour = 
182.61%). £30 per hour (excluding qualifications) 
multiplied by 182.61% 
Occupational therapist telephone contact 18.3 2 assume same proportion of costs as a GP telephone 
call (61% (*0.61)) 
Psychiatrist at surgery contact 171.4 1 TMHCSOPFUAF tab (Mental Health Consultant 
Services (Outpatient Setting) - Follow-up 
Attendance Face to Face) - MHOPFUA2 (Adult 
other services) 
Psychiatrist at home contact 248.53 1 based on psychiatrist visit cost above but use the 
proportion of home visiting from community nurse 
(p175, PSSRU) - £61:£42 = 1.45 SO - 
166*1.45=240.70 
Psychiatrist telephone contact 51.626 1 TMHCSOPFUANF tab (Mental Health Consultant 
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Services (Outpatient Setting) - Follow-up 
Attendance Non Face to Face) - MHOPFUA2 
(Adult other services) 
Psychologist at surgery contact 136 2 p171 PSSRU - £136 per hour of client contact - 
assume 1 hour appointment, Excludes qualification 
costs. 
Psychologist at home contact 189.04 2 based on psychologist visit cost above but use the 
proportion of district nurse home visit hour / clinic 
hour proportion from PSSRU 2010 (68/49=139%) 
Psychologist telephone contact 40.8 2 assume same proportion of costs as a psychiatrist 
face to face v non face to face (30% (*0.30)) 
Psychotherapist at surgery contact 136 2 Assume same as a psychologist. "A psychotherapist 
may be a psychiatrist, social worker, psychologist, 
mental health nurse or other mental health 
professional who has had further specialist training 
in psychotherapy. Increasingly, there are a number 
of psychotherapists who do not have backgrounds 
in these fields but who have undertaken in-depth 
training in this area. 
 
" - from http://www.nhscareers.nhs.uk/explore-by-
career/psychological-therapies/careers-in-
psychological-therapies/psychotherapist/ - accessed 
16April2013 
Psychotherapist at home contact 189.04 2 based on psychotherapist visit cost above but use 
the proportion of district nurse home visit hour / 
clinic hour proportion from PSSRU 2010 
(68/49=139%) 
Psychotherapist telephone contact 40.8 2 assume same proportion of costs as a psychiatrist 
face to face v non face to face (30% (*0.30)) 
Counsellor at surgery contact 59 2 P53 Pssru - £59 per consultation 
Counsellor at home contact 82.01 2 based on surgery visit cost above but use the 
proportion of district nurse home visit hour / clinic 
hour proportion from PSSRU 2010 (68/49=139%) 
Counsellor telephone contact 35.99 2 assume same proportion of costs as a GP telephone 
call (61% (*0.61)) 
Social worker at surgery contact 78 2 P190 - PSSRU - social worker adult services - £156 
per hour of face to face contact - assume 30 min 
appointment - excludes qualifications. 
Social worker at home contact 108.42 2 based on social worker visit cost above but use the 
proportion of district nurse home visit hour / clinic 
hour proportion from PSSRU 2010 (68/49=139%) 
Social worker telephone contact 23.4 2 assume same proportion of costs as a psychiatrist 
face to face v non face to face (30% (*0.30)) 
Home help/ care worker at surgery contact 11.58 2 same as surgery 
Home help/ care worker at home contact 11.58 2 P193 PSSRU - Home care worker per hour of face 
to face contact, Weighted average accounting for 
different rates for day/evening/weekday/weekends. 
Plus, info that over 50% of visits are for 30 minutes 
so accounting for this (23.16/2= £11.58) 
Home help/ care worker telephone contact 7.0638 2 assume same proportion of costs as a GP telephone 
call (61% (*0.61)) 
Meals on Wheels at surgery contact 5 2 same as home visit 
Meals on Wheels at home contact 5 2 P125 PSSRU - £6 local authority meal v £4 
independent sector cost per day 
Meals on Wheels telephone contact 3.05 2 assume same proportion of costs as a GP telephone 
call (61% (*0.61)) 
Pharmacist for advice at surgery contact 4.17 2 p172 PSSRU - £50 - assume 5 min consultation - 
Excludes qualification costs. 
Pharmacist for advice at home contact 4.17 2 same as home visit 
Pharmacist for advice telephone contact 4.17 2 Assume same as a pharmacist surgery consult 
NHS direct at surgery contact 22.358 4 cost as telephone 
NHS direct at home contact 22.358 4 cost as telephone 
NHS direct telephone contact 22.358 4 21.02 in 2009/10 so inflate up to 2011/12 
     
Insulin equipment     
Blood glucose monitor / metre item 12 5  
Blood glucose testing strips 100-pack 30.1 6 per 100: p459 - accu-chek mobile - n100 
Insulin pen item 15.7 6 per 1 pen: p446 - autopen 24 
Insulin pump item 2375 7  
Needle 100-pack 2.79 1 per 100: p447 - hypodermic needle - n100 
Syringe 10-pack 1.35 6 per 10; p447 - U100 syringe with needle - 10 
needles - 1.35 
Finger prick device 200-pack 2.94 6 p446 - unilet eco – 200 
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Sources 
1. NHS. NHS trust reference cost schedules 2010-11, inflated up to 2011-12 prices using the retail price 
inflation percentage from PSSRU 2012/13.  
http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH_13114
0 Last accessed 19/02/13. 
2. PSSRU. Unit Costs of Health & Social Care 2012. http://www.pssru.ac.uk/archive/pdf/uc/uc2012/full-with-
covers.pdf Last accessed 27/02/13. 
3. Optical Confederation. Optics at a Glance. Dec 2011. http://www.fodo.com/downloads/Optics-at-a-
glance_Dec2011_web.pdf  Last accessed 03/05/13. 
4. NHS Direct. NHS Direct Business Plan 2010-11. 
http://www.nhsdirect.nhs.uk/CorporateInformation/OperatingStatistics/AnnualReport2010-2011 Last 
accessed 03/05/13. 
5. Boots. Blood glucose metre. http://www.boots.com/en/iBGStar-blood-glucose-meter_1253400/ Last 
accessed 23/06/14. 
6. Joint Formulary Committee. British National Formulary. March 2012. 63rd edition. London: BMJ Group 
and Pharmaceutical Press. 
7. Diabetes.co.uk. Cost of Insulin Pumps. http://www.diabetes.co.uk/insulin-pumps/buying-an-insulin-
pump.html Last accessed 23/06/14.
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4.4 Sensitivity Analyses 855 
Table S11: Total costs at baseline and 18 months including intervention costs based on sensitivity analyses (2011/12 prices; all 18 month costs except intervention 856 
costs discounted) 857 
  Control  Intervention Unadjusted 
mean  
95% C.I. Adjusted 
mean  
95% C.I.$ 
 valid n Mean £ SD valid n Mean £ SD difference$  difference$$  
Costs at 18 months           
Per protocol           
Health & social care costs 
including intervention costs  
107 1025 573 92 1184 572 159 -39 to 357 151 -32 to 334 
GP Clustering           
Health & social care costs 
including intervention costs 
107 1025 573 92 1184 572 159 -39 to 357 150 -30 to 329 
Alternative intervention cost           
Health & social care costs 
including intervention costs 
107 1025 573 92 1095 572 70 -128 to 268 61 -123 to 244 
Intention to treat           
Health & social care costs 
including intervention costs – 
intention to treat 
170 1052 497 164 1126 473 74 -42 to 190 107 7 to 207* 
$Comparisons include clustering for nurse. $$Comparisons include clustering for nurse plus covariates for baseline cost, age, gender, marital status, ethnicity, duration of 858 
diabetes and baseline utility. * Statistically significant 859 
 860 
Table S12: Outcomes at baseline and 18 months interpolated to a six month period to match the cost data based on sensitivity analyses 861 
  Control  Intervention Unadjusted 
mean  
95% C.I. Adjusted 
mean  
95% C.I.$ 
 valid n Mean 
£ 
SD valid n Mean 
£ 
SD difference$  difference$$  
Outcomes at 18 months           
Per protocol           
HbA1c (discounted) 109 71.31 19.22 110 71.60 18.11 0.29 -5.40 to 5.98 0.00 -6.08 to 6.09 
SF12 based QALY (discounted 
and interpolated) 
48 0.36 0.06 58 0.37 0.06 0.01 -0.01 to 0.03 0.00 -0.01 to 0.02 
GP cluster           
HbA1c (discounted) 109 71.31 19.22 110 71.60 18.11 0.29 -5.38 to 5.97 0.66 -5.43 to 6.75 
SF12 based QALY (discounted 
and interpolated) 
48 0.36 0.06 58 0.37 0.06 0.01 -0.01 to 0.03 0.00 -0.01 to 0.00 
Intention to treat           
HbA1c (discounted) 170 72.16 16.74 164 72.19 15.61 0.02 -4.34 to 4.39 0.47 -4.75 to 3.82 
SF12 based QALY (discounted 170 0.36 0.06 164 0.37 0.06 0.00 -0.01 to 0.02 0.00 -0.00 to 0.01 
60 
 
and interpolated) 
$Comparisons include clustering for nurse. $$Comparisons include clustering for nurse plus covariates for age, gender, marital status, ethnicity, duration of diabetes and 862 
baseline utility. * Statistically significant 863 
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4.5 Cost-effectiveness 864 
For the economic analysis, 139 (42%) and 85 (25%) participants had the two necessary combinations of cost/HbA1c/covariate and cost/SF-865 
12/covariate data, respectively; characteristics of those with and without data were comparable. 866 
 867 
Based on QALYs, probabilities of cost-effectiveness for the D6 group at 18 months did not exceed 35% at the examined willingness to pay 868 
thresholds. However, based on HbA1c, probabilities of cost-effectiveness were around 5% at a willingness to pay threshold of £0, rising to (and 869 
remaining at) around 65% at thresholds of £5000–£50000. However, willingness to pay for a point improvement in HbA1c is unknown, and such 870 
a small improvement is unlikely to be clinically meaningful. Based on QALYs, probabilities of cost-effectiveness for the D6 group at 18 months 871 
did not exceed 35% at the examined willingness to pay thresholds. However, based on HbA1c, probabilities of cost-effectiveness were around 872 
5% at a willingness to pay threshold of £0, rising to (and remaining at) around 65% at thresholds of £5000–£50000. However, willingness to pay 873 
for a point improvement in HbA1c is unknown, and such a small improvement is unlikely to be clinically meaningful. 874 
 875 
 876 
 877 
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Figure S1: Cost-effectiveness plane for 
HbA1c changes at 18 months from a health 
& social care perspective 
Figure S2: Cost-effectiveness plane for 
QALY gains at 18 months from a health & 
social care perspective 
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Figure S3: Cost-effectiveness acceptability 
curve for HbA1c point improvements at 18 
months from a health & social care 
perspective 
Figure S4: Cost-effectiveness acceptability 
curve QALY gains at 18 months from a 
health & social care perspective  
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